GSK – Strong first quarter prompts another upgrade Derren Nathan, head of equity research, Hargreaves Lansdown: “GSK has started 2024 in rude health. Strong growth in vaccine and speciality medicines…
GSK – Strong first quarter prompts another upgrade Derren Nathan, head of equity research, Hargreaves Lansdown: “GSK has started 2024 in rude health. Strong growth in vaccine and speciality medicines…